Monday, 3 December 2012

SPA Directory Part 3: L-R

Here is the 3rd portion of the SPA Directory for companies L-R.  As always I welcome your comments on any SPA agreements that are not shown here, especially active ongoing studies.

LCILannettC-TopicalLocal anesthesiahttp://www.streetinsider.com/Corporate+News/Lannett+(LCI),+FDA+Reach+Agreement+Over+SPA+for+C-Topical+Phase+III/7054155.htmlYESn/an/a
nilLantheusFlurpiridaz F18Myocardial perfusion imaginghttp://www.lantheus.com/News-Press-2011-0311.htmlYeshttp://www.clinicaltrials.gov/ct2/show/NCT01347710?term=Flurpiridaz+F18&rank=1Dec-12
CSE:VELO LifeCycle PharmaLCP-TacroKidney Transplanthttp://www.news-medical.net/news/20100812/FDA-grants-LifeCycle-Pharma-SPA-for-LCP-Tacro-pivotal-Phase-3-study-in-de-novo-kidney-transplant-patients.aspxYeshttp://www.clinicaltrials.gov/ct2/show/NCT01187953?term=LCP-tacro&rank=8Mar-13
nilMacrocureCureXcellChronic diabetic ulcershttps://sos.cision.com/node/499686Yeshttp://www.clinicaltrials.gov/ct2/show/NCT01421966?term=macrocure&rank=3Feb-15
TSE:4508Mitsubishi Tanabe Pharma CoCollategeneAdvanced PADhttp://www.anges-mg.com/en/news/pdf/20121024.pdfYesn/an/a
nilNanotherapeuticsRamoplaninC Diffhttp://www.nanotherapeutics.com/products_pipeline_ramoplanin.phpYesn/an/a
NLNKNew Link GeneticsHyperAcute immunotherapyPancreatic cancerhttp://www.linkp.com/products/hyperacute-pancreas.htmlYeshttp://www.clinicaltrials.gov/ct2/show/NCT01072981?term=hyperacute+pancreas&rank=1Jan-14
nilNovaRxLucanixAdvanced NSCLChttp://www.prnewswire.com/news-releases/novarx-completes-enrollment-in-lucanix-pivitol-phase-iii-therapeutic-vaccine-trial-for-post-frontline-maintenace-therapy-in-non-small-cell-lung-cancer-159688685.htmlYeshttp://www.clinicaltrials.gov/ct2/show/NCT00676507?term=NovaRx&rank=2Oct-12
OXGIOncogenixCustirsenCancer pain in mCRPChttp://oncogenex.com/physicians/custirsen-ogx-011Yeshttp://www.clinicaltrials.gov/ct2/show/NCT01188187?term=Custirsen&rank=6Dec-13
nilOnconovaEstybonMyelodysplastic Syndromes http://www.eurekalert.org/pub_releases/2010-10/poc-oaf100410.phpYeshttp://www.clinicaltrials.gov/ct2/show/NCT01241500?term=onconova&rank=13Oct-13Interim analysis
ONXXOnyx PharmaCarfilzomib2L MM +lenolidomidehttp://www.onyx.com/view.cfm/626/onyx-pharmaceuticals-receives-fda-accelerated-approval-of-kyprolis-carfilzomib-for-injection-Yeshttp://www.clinicaltrials.gov/ct2/show/NCT01568866?term=carfilzomib&phase=2&rank=1Jan-15
OREXOrexigenContraveObesityhttp://ir.orexigen.com/phoenix.zhtml?c=207034&p=irol-newsArticle&id=1656731Yeshttp://www.clinicaltrials.gov/ct2/show/NCT01601704?term=orexigen&rank=1Sep-13
OXGNOxigeneZybrestat Anaplastic Thyroid Cancerhttp://investor.oxigene.com/releasedetail.cfm?ReleaseID=707372Yeshttp://www.clinicaltrials.gov/ct2/show/NCT01701349?term=oxigene&rank=5Dec-16
nilParatekOmadacyclineABSSSIhttp://www.paratekpharm.com/press/032812_SPA_ECCMID_release.pdfYesn/an/a
nilParatekOmadacyclineCABPhttp://www.paratekpharm.com/press/032812_SPA_ECCMID_release.pdfYesn/an/a
n/aPervasisVascugelFistula/Graft failure preventionhttp://www.prnewswire.com/news-releases/pervasis-receives-fda-fast-track-status-for-vascugel-to-prevent-arteriovenous-access-failure-in-patients-undergoing-hemodialysis-115553949.htmlYesn/an/a
PXSLPharmaxisBronchitolBronchiectasishttp://www.prnewswire.com/news-releases/pharmaxis-concludes-special-protocol-assessment-with-fda-for-bronchitol-phase-3-trial-57511597.htmlYeshttp://www.clinicaltrials.gov/ct2/show/NCT00669331?term=pharmaxis&phase=2&rank=4Jun-13
nilPolaris GroupADI-PEG 20Advanced HCChttp://www.prnewswire.com/news-releases/fda-approves-special-protocol-assessment-for-phase-3-trial-of-polaris-groups-cancer-therapeutic-adi-peg-20-in-the-treatment-of-hepatocellular-carcinoma-118979494.htmlYeshttp://www.clinicaltrials.gov/ct2/show/NCT01287585?term=Polaris+group&rank=1&submit_fld_opt=Jun-13
PVCTProvectusRose BengalMelanomahttp://www.pvct.com/pressrelease.html?article=20121002pendingn/an/a
RPTPRaptorDR CysteamineNephropathic Cystinosishttp://ir.raptorpharma.com/releasedetail.cfm?releaseid=633905Yeshttp://www.clinicaltrials.gov/ct2/show/NCT01000961?term=raptor&rank=11Jun-11
RPRXReprosAndroxalHypogonadismhttp://www.reprosrx.com/pr_20120912_repros_updates_androxal_phase_3.phpYeshttp://www.clinicaltrials.gov/ct2/show/NCT01534208?term=REPROS&rank=30Jul-13

Friday, 30 November 2012

SPA Directory Part 2

Thank-you to everyone who has taken the time to review my last posting.  Below is an update to the directory for companies D-K.

TASE:DPRMD-PharmDP-b99Acute Ischemic Strokehttp://www.dpharm.com/News.asp?mode=1&type=0&id=133&Year=2011Yeshttp://www.clinicaltrials.gov/ct2/show/NCT00893867?term=D-Pharm&rank=3Feb-13Futility analysis
ENDPEndo PharmaUrocidinBladder cahttp://bioniche.com/news_item.cfm?id=2215http://www.clinicaltrials.gov/ct2/show/NCT01284205?term=bioniche&rank=5&submit_fld_opt=n/aStudy withdrawn
EPCTEpiceptCepleneAMLhttp://investor.epicept.com/releasedetail.cfm?ReleaseID=604432Pendingn/an/a
EPCTEpiceptAmiketCIPNhttp://investor.epicept.com/releasedetail.cfm?ReleaseID=641427Pendingn/an/a
nilEssentialisDiazoxide Choline CRVHTG'shttp://essentialistherapeutics.com/media/Essentialis%20SPA%20Press%20Release%2010-25-10.pdfYeshttp://www.clinicaltrials.gov/ct2/show/NCT00973271?term=Essentialis&rank=5Jun-14My estimate
GALEGalenaNeuVaxEarly stage node+ low-expression HER2 breast cancerhttp://www.galenabiopharma.com/pipelineYeshttp://www.clinicaltrials.gov/ct2/show/NCT01479244?term=NeuVax&rank=1May-15
GNBTGenerexAE37Breast Cancerhttp://www.prnewswire.com/news-releases/generex-provides-update-on-company-initiatives-including-the-ae37-breast-cancer-vaccine-program-179098191.htmlPendingn/an/a
nilHelsinnNetupitant and PalonosetronCINVhttp://www.prnewswire.co.uk/news-releases/fda-agrees-to-special-protocol-assessment-spa-to-evaluate-the-safety-and-efficacy-of-a-fixed-dose-combination-fdc-of-netupitant-and-palonosetron-in-the-prevention-of-cinv-156836265.htmlYeshttp://www.clinicaltrials.gov/ct2/show/NCT01376297?term=Netupitant&rank=1Sep-12
nilHyperion TherapeuticsHPN-100Urea Cycle Disordershttp://files.shareholder.com/downloads/AMDA-1412CE/0x0x585109/0f970e6e-64cd-430e-9796-995fcab86980/HPTX_News_2012_7_7_General_Releases.pdfYeshttp://www.clinicaltrials.gov/ct2/show/NCT00992459?term=HPN-100&rank=3Aug-10
LSE:IMMImmupharmaLupuzorSLEhttp://www.immupharma.org/lupuzorYesn/an/a
nilInnocollCogenziaWound infectionshttp://innocollinc.com/cogenzia.htmlYesn/an/a
INSVInSite VisionDexasite/AzasiteBlepharitishttp://phx.corporate-ir.net/phoenix.zhtml?c=86061&p=irol-newsArticle&ID=1631034&highlight=Yeshttp://www.clinicaltrials.gov/ct2/show/NCT01408082?term=Insite+vision&rank=5&submit_fld_opt=Dec-12
ISA.TOIsotechnika PharmaVoclosporinKidney Transplanthttp://www.isotechnika.com/dnn/LinkClick.aspx?fileticket=UrRyyein3D8%3D&tabid=92&mid=671Yeshttp://www.clinicaltrials.gov/ct2/show/NCT01586845?term=voclosporin&rank=1Mar-15
nilISTA Pharma/B&LRemuraDry Eye Syndromehttp://www.prnewswire.com/news-releases/ista-pharmaceuticals-initiates-phase-3-clinical-program-for-remura-in-dry-eye-disease-103037129.htmlYeshttp://www.clinicaltrials.gov/ct2/show/NCT01212471?term=ISTA+bromfenac&rank=4Dec-11
KERXKeryxZerenexHyperphosphatemia in ESRDhttp://www.keryx.com/page.cfm?hmid=20&smid=0&pg=4bYeshttp://www.clinicaltrials.gov/ct2/show/NCT01191255?term=zerenex&rank=2Dec-12

Thursday, 29 November 2012

SPA Tracker Part 1

I have been spending some time researching companies who have a SPA agreement in place and am compiling a database which I plan to share on my blog.  So far I have about 70 companies with an agreement in place or an agreement pending FDA review.  Interestingly, I have found a significant number of companies either experience a significant delay between receiving the agreement and commencing the study, or cease operations before the the trial is ever started.  The database is a work in progress so I will be publishing it in parts alphabetically.  Here are entries from A-C:

TickerCompanyCompound IndicationSourceSPA AgreementNCT linkPrimary End Date
ASTMAastrom
ixmyelocel-T
End stage CLIhttp://investors.aastrom.com/releasedetail.cfm?ReleaseID=652908http://www.clinicaltrials.gov/ct2/show/NCT01483898?term=ixmyelocel-T&rank=1Mar-15
nilACT BiotechTelatonibGastric cahttp://www.actbiotech.com/FINALACTASCO2011PR2.pdfYesn/an/a
ACUSAcusphere
Imagify
Coronary Imaginghttp://www.acusphere.com/press_releases/ACUS_SPA_agreeement_FINAL.pdfYesn/an/a
ADLSAdvanced Life Sciences
Restanza
CABPCompany suspended operations in 5/2011Yesn/an/a
AEZSAeterna ZentarisAEZS-108Endometrial cahttp://www.aezsinc.com/en/page.php?p=60&q=543Pendingn/an/a
AGX:DE  OTN:GAGXFAgennixTalactoferrin alfa1L NSCLChttp://www.fiercebiotech.com/press-releases/agennix-receives-fast-track-designation-fda-talactoferrin-combination-sunitinib-ren-0Yeshttp://www.clinicaltrials.gov/ct2/show/NCT00706862?term=FORTIS-C&rank=1Jun-15
CMXICytomedix(Aldagen)ALD-301Critical limb ischemiahttp://www.intersouth.com/news/aldagen-reaches-agreement-with-fda-on-a-special-protocol-assessment-spa-for-phase-3-trial-of-ald-301-for-critical-limb-ischemiaYesn/an/a
NPCUFAllonDavunetideProgressive Supranuclear Palsyhttp://www.allontherapeutics.com/2012/11/patient-treatment-completed-in-pivotal-trial-evaluating-allons-davunetide/Yeshttp://www.clinicaltrials.gov/ct2/show/NCT01110720?term=Davunetide&rank=4&submit_fld_opt=Dec-12
ALSE/NAVBAlseres Pharma/NavideaAltropaneParkinson's disease imaginghttp://ir.alseres.com/releasedetail.cfm?ReleaseID=375770Yeshttp://www.clinicaltrials.gov/ct2/show/NCT00724906?term=Altropane&rank=2n/a
APRIApricus BioPrevOncoTHCChttp://www.apricusbio.com/press_02172011.htmlNever concluded n/an/a
ABIOARCA BiopharmaBucindololChronic heart failurehttp://www.businesswire.com/news/home/20100517005854/en/ARCA-Announces-Special-Protocol-Assessment-Agreement-FDAYesn/an/a
nilArgos TherapeuticsAGS-003mRCChttp://globenewswire.com/news-release/2012/07/02/272515/260946/en/Argos-Therapeutics-Receives-FDA-Approval-of-Special-Protocol-Assessment-for-AGS-003-Phase-3-Trial.htmlYeshttp://www.clinicaltrials.gov/ct2/show/NCT01582672?term=Argos+therapeutics&rank=8Jun-14
ARQLArquleTivantinibHCChttp://investors.arqule.com/common/mobile/iphone/releasedetail.cfm?ReleaseID=713700&CompanyID=ARQL&MobileID=#Yesn/an/a
OMX:BAVABavarian NordicProstvacmCRPChttp://www.bavarian-nordic.com/investor/announcements/2010-40.aspxYeshttp://www.clinicaltrials.gov/ct2/show/NCT01322490?term=Prostvac&rank=1Dec-14
BIIBBiogenPegylated interferonMShttp://www.biotechnologyevents.com/node/1720Yeshttp://www.clinicaltrials.gov/ct2/show/NCT00906399?term=Biogen+BIIB017&phase=2&rank=1Oct-12
BPAXBioSanteLibigelHSDDhttp://www.biosantepharma.com/News-Releases.php?ID=061112Pendingn/an/a
nilCell>Point
technetium-99m-EC-G
Lung cancer imaginghttp://cellpointweb.com/blog/cellpoint-announces-agreement-with-the-fda-on-a-special-protocol-assessment-for-the-phase-3-technetium-99m-ec-g-lung-cancer-imaging-trial/Yeshttp://www.clinicaltrials.gov/ct2/show/NCT01394679?term=technetium-99m&phase=2&fund=2&rank=9Jun-13
CLSNCelsionThermodoxHCChttp://www.prnewswire.com/news-releases/celsion-receives-fast-track-designation-for-thermodox-development-program-to-treat-primary-liver-cancer-101369159.htmlYeshttp://www.clinicaltrials.gov/ct2/show/NCT00617981?term=THERMODOX&rank=4Dec-12
nilCold GenesysCG0070Non muscle invasive bladder cancerhttp://www.businesswire.com/news/home/20120911005169/en/Cold-Genesys-Announces-Agreement-FDA-Special-ProtocolYeshttp://www.clinicaltrials.gov/ct2/show/NCT01438112?term=CG0070&rank=2Dec-16
CRMDCorMedixCRMD001Contrast-Induced Acute Kidney Injuryhttp://www.cormedix.com/pipeline_CRMD001.phpYeshttp://www.clinicaltrials.gov/ct2/show/NCT01391520?term=CRMD001&rank=2n/a
CYCC/PCyclacelSapacitabineAMLhttp://investor.cyclacel.com/releasedetail.cfm?ReleaseID=614179Yeshttp://www.clinicaltrials.gov/ct2/show/NCT01303796?term=SEAMLESS+cyclacel&rank=1Oct-14
CYTRCytRx
Tamibarotene
Acute Promyelocytic Leukemiahttp://www.cytrx.com/aboutYeshttp://www.clinicaltrials.gov/ct2/show/NCT00520208?term=STAR-1&rank=1Dec-12

I'll be adding to the list periodically and updating so please feel free to comment if there are any companies beginging with A-C that I may have missed.  I would welcome input into expected dates for completion where I have blanks.  I will be compiling a summary review once the whole list is published and welcome your comments.